Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
BELLICUM PHARMACEUTICALS, INC (BLCM) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/10/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update"
11/04/2021 8-K Quarterly results
Docs: "Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update"
08/12/2021 8-K Quarterly results
Docs: "Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update"
03/30/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update Raised gross proceeds of $69.6 million from public offering and private placement option fee Narrowed strategic focus to core GoCAR-T ® cell therapy programs Cost saving initiatives underway to extend runway to meaningful GoCAR data readouts"
08/05/2019 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology Annual Meeting Rivo-cel TM achieved primary endpoint in BP-004 European registrational trial"
05/07/2019 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology Annual Meeting Rivo-cel TM on-track for topline data readout from BP-004 pediatric trial in second quarter of 2019"
03/12/2019 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018"
11/06/2018 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update"
05/08/2018 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results"
03/13/2018 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017",
"Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501 Company also reports encouraging disease-free survival and overall survival rates in pediatric patients with primary immunodeficiencies A pediatric registration trial is being planned"
11/07/2017 8-K Quarterly results
Docs: "Bellicum Reports Third Quarter 2017 Financial Results"
08/08/2017 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update Company updates BPX-501 program Enrollment progressing in early clinical trials of CAR T and TCR product candidates Company to host conference call and webcast on August 8 at 5:00 PM EDT"
05/08/2017 8-K Form 8-K - Current report
03/13/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/08/2016 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update Two INDs cleared by FDA to begin studies of controlled CAR T and TCR product candidates Conference call and webcast to be held Monday, August 8, 2016 at 5 p.m. Eastern"
05/09/2016 8-K Form 8-K - Current report
03/14/2016 8-K Form 8-K - Current report
11/09/2015 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Program Updates Pediatric patients with beta thalassemia, SCID, and Wiskott-Aldrich Syndrome are disease-free following haplo transplant with BPX-501 T cells Additional details of ongoing BPX-501 trial and adoptive T cell programs to be presented at ASH 2015"
08/13/2015 8-K Quarterly results
Docs: "Conference call and webcast to be held Thursday, August 13, 2015 at 5 p.m. Eastern Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Second Quarter Ended June 30, 2015"
05/11/2015 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Reports First Quarter 2015 Financial Results"
03/11/2015 8-K Quarterly results
Docs: "Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for Fourth Quarter and Year Ended December 31, 2014"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy